GlobeNewswire

Verano Submits DEA Registration Applications for State-Licensed Medical Cannabis Businesses Following Landmark Federal Rescheduling Order
13/05/2026
CHICAGO, May 13, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the Company has submitted applications [...]
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
13/05/2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for [...]
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
13/05/2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral [...]
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
13/05/2026
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on [...]
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
13/05/2026
Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public offering of equity [...]
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue [...]
Seer Files Patent Infringement Lawsuit Against Nanomics
13/05/2026
Seer defends its pioneering Proteograph ® Product Suite intellectual property (IP) REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased [...]
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
13/05/2026
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 [...]
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
13/05/2026
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
13/05/2026
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can- [...]
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
13/05/2026
Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues ; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company [...]
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
13/05/2026
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - - Phase 1 SAD and MAD [...]
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
13/05/2026
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 — --Company to host conference call and webcast today at 8: [...]
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
13/05/2026
Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose [...]
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/05/2026
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 ( [...]
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – – Obexelimab Phase 3 INDIGO [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
13/05/2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies
13/05/2026
$55 Million Series B to Advance Quantum for Healthcare ULM, Germany, May 13, 2026 (GLOBE NEWSWIRE) -- NVision , a leader in quantum technologies for healthcare, today announced a $55 million Series B financing round [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum